SBIR/STTR Research Award

SEVERAL RECENT REPORTS SUGGEST THAT EXTRACORPOREAL PERFUSION OF TUMOR BEARING PLASMA OVER PROTEIN A CONTAINING SUBSTRATES CAN RESULT IN OBJECTIVE TUMOR REGRESSION IN THE HOST.

Award identifier 542791277d7d417d5a69e003fa58492d127c1cb838450b656162934e50e03516Awarding agency Department of Health and Human Services

Award amount

$45,720

Program and phase

SBIR · Phase I

Award year

1984

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Imr+e Corpon
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

SEVERAL RECENT REPORTS SUGGEST THAT EXTRACORPOREAL PERFUSION OF TUMOR BEARING PLASMA OVER PROTEIN A CONTAINING SUBSTRATES CAN RESULT IN OBJECTIVE TUMOR REGRESSION IN THE HOST. IN THE PRESENT INVESTIGATION, PURIFIED STAPHYLOCOCCAL PROTEIN A IS ISOLATED, COUPLED TO AN INERT BIOCOMPATIBLE SILICA SUBSTRATE, HOUSED IN A DISPOSABLE CARTRIDGE, STERILIZED AND USED TO TREAT MALIGNANCY. A SIMILAR SYSTEM HAS BEEN UTILIZED BY INVESTIGATORS AND RESULTED IN OBJECTIVE TUMOR REGRESSIONS IN PATIENTS WITH BREAST ADENOCARCINOMA (BENSINGER ET AL., NEW ENG. J. MED. 306: 935, 1982). PATIENTS TO BE STUDIED IN THIS RESEARCH GRANT PROPOSAL WILL HAVE STAGE II BREAST CANCER AND STAGE II MELANOMA. IDEAL PATIENTS WILL HAVE LOCAL SKIN METASTASES OR RECURRENCE THAT CAN BE DIRECTLY OBSERVED FOR ANTI-TUMOR EFFECTS AND CAN BE BIOPSIED. IN THE SIX MONTH PERIOD COVERED BY THIS PROPOSAL, IT IS ESTIMATED THAT 14 PATIENTS COULD BE TREATED AND STUDIED EMPLOYING EXTRACORPOREAL PROTEIN A IMMUNOADSORPTION. THE OBJECTIVES OF THIS STUDY ARE TO COLLECT PATIENT SERA BEFORE AND DURING EXTRACORPOREAL IMMUNOADSORPTION AND TO ANALYZE THE SERA FOR QUANTITATIVE CHANGES IN IMMUNOGLOBULIN LEVELS, TOTAL HEMOLYTIC COMPLEMENT LEVELS, CIRCULATING IMMUNE COMPLEXES, AND TUMOR IMMUNITY (WHEN APPROPRIATE). THESE IMMUNOLOGIC PARAMETERS WILL BE ASSESSED IN ASSOCIATION WITH PHYSICAL EXAMINATIONS, MEASUREMENT OF OBJECTIVE TUMOR (WHEN APPROPRIATE), AND X-RAYS OF AREAS OF TUMOR INVOLVEMENT. IN ADDITION, PROTEIN(S) BOUND TO THE PROTEIN A IMMUNOADSORPTION WILL BE ANALYZED FOR THE PRESENCE OF IMMUNOGLOBULIN, COMPLEMENT COMPONENTS, AND IMMUNE COMPLEXES. THESE ANALYSES WILL ENABLE US TO DETERMINE IF THERE IS A MODIFICATION IN THE BIOLOGIC RESPONSE AS A RESULT OF EXTRACORPOREAL PROTEIN A IMMUNOADSORPTION WHICH IS ASSOCIATED WITH CLINICAL IMPROVEMENT AND WILL ASSIST IN THE DEVELOPMENT OF A SAFE COMMERCIALLY AVAILABLE TREATMENT DEVICE. THIS IS A STUDY TO EVALUATE THE TUMOR BEARING PATIENT BEFORE AND AFTER EXTRACORPOREAL TREATMENT IN A BASIC RESEARCH PHASE I PROPOSAL WITH SPECIFIC AIMS DIRECTED TOWARD THE DEVELOPMENT OF A SAFE AND EFFICACIOUS TREATMENT UNIT AND PRELIMINARY ELUCIDATION OF POSSIBLE MODE(S) OF ACTION.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.